Leading Article

Dapsone in Henoch-Schönlein purpura – worth a trial

B.I. Hoffbrand

Whittington Hospital, London N19 3UA, UK

Dapsone and other sulphone drugs have been important therapeutic agents in dermatitis herpetiformis for over 40 years and have subsequently been used in a variety of dermatological conditions. Dapsone appears to be of especial value in diseases characterized by an accumulation of polymorphonuclear neutrophils notably with leucocytoclastic vasculitis, a feature of erythema elevatum diitium, urticarial vasculitis and allergic vasculitis.

The most clearly delineated condition with prominent cutaneous leucocytoclastic vasculitis which presents to general physicians (and paediatricians) is Henoch-Schönlein purpura. In 1983 we presented what appear to be the first reported cases of Henoch-Schönlein purpura treated with dapsone to good effect. Subsequently, Chamoud and colleagues gave dapsone to a 69 year old man with leucocytoclastic vasculitis and gastrointestinal purpura with a rapid resolution of abdominal symptoms and the evidence of a protein-losing enteropathy.

In the past year we have seen two further patients with Henoch-Schönlein purpura who have responded dramatically to dapsone. The first, a 24 year old man, developed the characteristic skin lesions with abdominal pain, fever and arthritis following a sore throat. He was investigated in the department of rheumatology of a London teaching hospital and shown on skin biopsy to have leucocytoclastic vasculitis. The fever and, much later, the abdominal pain subsequently cleared but he had a total of 18 weeks off work. When we first saw him 7 months after the onset, he still had recurrent ‘palpable purpura’ involving his forearms as well as his legs, and painful swollen ankles. Within 24 hours of starting dapsone 100 mg/day the ankle pain cleared followed by the upper limb purpura a few days later. The dose was reduced over the next 2 months and then stopped. During this time and over the following 10 months there have been occasional sparse crops of purpura around the ankles associated with standing for long periods, without the need for further dapsone. The second patient was a 15 year old Taiwanese schoolboy, under the care of the paediatric department of the same hospital, with palpable purpura, arthralgia, vomiting and diarrhoea followed by recurrent abdominal pain. He had been away from school for 3 weeks. Within 3 hours of the first 50 mg tablet of dapsone the abdominal pain disappeared. There was no recurrence of purpura or rash with just one week of dapsone 50 mg/day. He returned to school the day after starting treatment.

The mechanism of action of dapsone in leucocytoclastic vasculitis is unknown. There is evidence that it has an antioxidant scavenger effect and may also suppress the generation of toxic free radicals in polymorphonuclear neutrophils. Actions in inhibiting prostaglandin PGD2 production and the synthesis of IgG and IgA antibodies may also be relevant. The latter two properties of dapsone may be of particular importance for its use in Henoch-Schönlein purpura as a number of observations have been made which point to an immune dysregulation, primarily of IgA production, in this condition, whilst there are disturbances of prostaglandin metabolism in acute Henoch-Schönlein purpura which may contribute to the inflammatory process.

There is general agreement that corticosteroids are of limited value in conditions characterized by leucocytoclastic vasculitis. Dapsone, on the other hand, appears to be effective and safe in relatively small doses. The evidence that dapsone may be of value in Henoch-Schönlein purpura is limited to the evidence presented here and does not include any pointers to a possible effect on associated glomerulonephritis. There is also no evidence that dapsone is curative or does other than reduce the inflammatory process and provide symptomatic relief. However, in a condition with no treatment of proven value, there appears to be enough evidence to justify a trial of dapsone for symptom relief and for the possible life threatening complications of gut purpura and severe glomerulonephritis. The possibility that Henoch-Schönlein purpura is a systemic form of IgA nephropathy...
raises considerations (though certainly premature ones) of the use of dapsone in the latter disorder. As we suggested in 1983,11 the proven value of dapsone in leucocytoclastic vasculitis should be more widely appreciated in general medical practice and the place of dapsone in the treatment of Henoch-Schönlein purpura should be further assessed.

References

Dapsone in Henoch-Schönlein purpura—worth a trial.
B. I. Hoffbrand

doi: 10.1136/pgmj.67.793.961

Updated information and services can be found at:
http://pmj.bmj.com/content/67/793/961.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/